Regeneron rises after ruling in patent fight with Viatris

The United States District Court for the Northern District of West Virginia concluded that Regeneron (REGN) has demonstrated by a preponderance of the evidence that the defendants, Mylan Pharmaceuticals, have infringed claims 4, 7, 9, 11, 14, 15, 16, and 17 of the ‘865 Patent, according to a ruling posted by the court dated December 27. Regeneron has demonstrated by a preponderance of the evidence that the defendants will induce infringement of claims 6 and 25 of the ‘572 Patent and claims 11 and 19 of the ‘601 Patent, the ruling also states. Mylan, a Viatris (VTRS) unit, has demonstrated by “clear and convincing evidence” that certain claims some of the patents in question are “invalid as obvious,” the ruling also states. In afternoon trading, Regeneron shares are up $23.80, or 3%, to $873.33.